GoodRx (GDRX) to Release Quarterly Earnings on Wednesday

Key Points

• GoodRx is expected to announce its Q2 2025 earnings on August 6th, with analysts predicting earnings of $0.10 per share and revenue of $205.72 million.
• In its last quarterly earnings report, GoodRx reported $0.09 EPS, surpassing estimates, and a revenue increase of 2.6% year-over-year, reaching $202.97 million.
• Multiple firms have adjusted their price targets for GoodRx, with Goldman Sachs lowering its target to $5.00, while the stock maintains an average rating of "Moderate Buy" from analysts.

GoodRx (NASDAQ:GDRX - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect GoodRx to post earnings of $0.10 per share and revenue of $205.72 million for the quarter. GoodRx has set its FY 2025 guidance at EPS and its Q2 2025 guidance at EPS.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.04 by $0.05. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. GoodRx had a return on equity of 7.85% and a net margin of 3.57%. The company's quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.08 EPS. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $4.53 on Monday. The business's 50 day simple moving average is $4.58 and its 200-day simple moving average is $4.58. The firm has a market capitalization of $1.62 billion, a price-to-earnings ratio of 56.63, a price-to-earnings-growth ratio of 2.01 and a beta of 1.24. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.23 and a quick ratio of 5.23. GoodRx has a 12 month low of $3.67 and a 12 month high of $8.94.

Analyst Ratings Changes

GDRX has been the topic of a number of recent analyst reports. Wells Fargo & Company cut their price target on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Truist Financial dropped their target price on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. The Goldman Sachs Group dropped their target price on GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Finally, UBS Group dropped their target price on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.55.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction that occurred on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.17% of the company's stock.

Hedge Funds Weigh In On GoodRx

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of GoodRx by 124.4% during the 1st quarter. AQR Capital Management LLC now owns 282,320 shares of the company's stock valued at $1,245,000 after buying an additional 156,482 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of GoodRx by 7.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 783,378 shares of the company's stock valued at $3,455,000 after buying an additional 54,783 shares during the period. Finally, Jane Street Group LLC acquired a new stake in shares of GoodRx during the 1st quarter valued at $370,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.